×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$18.50
+0.17 (+0.93%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$17.83
$19.18
50-Day Range
$10.71
$18.50
52-Week Range
$10.41
$22.03
Volume
775,361 shs
Average Volume
727,322 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

Kura Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.4% Upside
$38.00 Price Target
Short Interest
Bearish
7.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
1.00mentions of Kura Oncology in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($2.18) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.40 out of 5 stars

Medical Sector

131st out of 1,428 stocks

Pharmaceutical Preparations Industry

52nd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Kura Oncology logo

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

KURA Stock News Headlines

Kura Oncology (NASDAQ:KURA) Stock Price Up 2.9%
Kura Oncology Stock Scores Rising Relative Strength
Kura Oncology Q1 2022 Earnings Preview
Kura Oncology: Q4 Earnings Insights
Kura Oncology: Q4 Earnings Snapshot
Kura Oncology Q4 2021 Earnings Preview
Kura Oncology CFO Marc Grasso to step down
Kura Oncology Expands Leadership Team with Key Promotions
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
121
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$38.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+105.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-130.47 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.61 per share

Miscellaneous

Free Float
63,371,000
Market Cap
$1.23 billion
Optionable
Optionable
Beta
1.06














Kura Oncology Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

What is Kura Oncology's stock price forecast for 2022?

6 Wall Street research analysts have issued 1-year price targets for Kura Oncology's shares. Their KURA stock forecasts range from $26.00 to $80.00. On average, they anticipate Kura Oncology's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 105.4% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

How has Kura Oncology's stock price performed in 2022?

Kura Oncology's stock was trading at $14.00 on January 1st, 2022. Since then, KURA shares have increased by 32.1% and is now trading at $18.50.
View the best growth stocks for 2022 here
.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Kura Oncology
.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its earnings results on Wednesday, May, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the business posted ($0.46) earnings per share.
View Kura Oncology's earnings history
.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO, Pres & Principal Financial Officer (Age 53, Pay $984.61k)
  • Ms. Kathleen Ford, Chief Operating Officer (Age 75, Pay $689.32k)
  • Dr. Marc Grasso M.D., Advisor (Age 48, Pay $651.68k)
  • Ms. Kirsten Flowers, Chief Commercial Officer (Age 47, Pay $642.98k)
  • Dr. Stephen Dale M.D., Chief Medical Officer (Age 50, Pay $811.58k)
  • Mr. Thomas Doyle, Principal Accounting Officer & Sr. VP of Fin. and Accounting (Age 51)
  • Mr. Pete De Spain, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Teresa Brophy Bair Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. James E. Basta J.D., Esq., Chief Compliance Officer & Corp. Sec. (Age 56)
  • Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $18.50.

How much money does Kura Oncology make?

Kura Oncology (NASDAQ:KURA) has a market capitalization of $1.23 billion. The company earns $-130.47 million in net income (profit) each year or ($1.990010) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 121 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for Kura Oncology is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.